From WisPolitics.com/WisBusiness.com …
— Drug overdose deaths in Wisconsin dropped nearly 17% in 2025, the latest CDC figures show.
The provisional estimates from the federal agency’s National Center for Health Statistics show Wisconsin had 976 drug overdose deaths in 2025, marking a decline of 16.79% from the prior year’s total of 1,173.
This continues a multi-year trend of falling overdose deaths in the state, which health officials attribute to greater availability of drug testing resources, overdose reversal medications, providing more resources to the hardest-hit communities and other strategies.
Annual overdose death totals for Wisconsin have dropped from recent highs of 1,772 in 2021, 1,817 in 2022 and 1,744 in 2023, earlier CDC figures show.
At the national level, overdose deaths have followed a similar pattern, with a total of 69,973 estimated for 2025. That’s down from 81,313 in the prior year.
— GenoPalate, a Milwaukee-based personal nutrition company, is adding telehealth services to its weight loss medication program through a partnership with Eden in Colorado.
The companies today announced the strategic partnership, through which GenoPalate members will get access to Eden’s telehealth service to determine if GLP-1 medications such as Ozempic are a good fit.
At the same time, members of Eden’s platform will be able to join GenoPalate’s “Thrive on GLP-1” four-month wellness program that includes nutrition guidance tailored to the client’s biology and lifestyle.
Dr. Asif Naseem, CEO of GenoPalate, says GLP-1 care is “entering its next chapter” as both companies are seeing rising demand from members for support with these medications. That includes how to manage nutrition with a reduced appetite due to the treatment, dealing with side effects, protecting muscle and more.
“People need to understand what their body requires, how to nourish themselves with a reduced appetite, how to manage changes along the way, and how to build habits that support lifelong wellness,” Naseem said in a statement.
A spokesperson for GenoPalate said the partnership has been formalized but declined to disclose specific financial terms. In addition to expanding access to each company’s core services, the partnership aims to create “a more complete care experience” for anyone taking or considering GLP-1 medications.
“That includes helping members better understand how prescription medication, personalized nutrition, biomarker insights, coaching, and long-term habit formation can work together as part of a more comprehensive approach to weight management,” the spokesperson wrote in an email.
Looking ahead, the partnership is expected to expand over time as GenoPalate is currently exploring in-club nutrition experiences within Eden Health Clubs, another brand under Eden Health International Inc.
Meanwhile, the companies are developing support programs for people on other prescription medications, including hormone replacement therapy for women.
“Future efforts include deeper program integration, joint member education and webinars, co-developed social media content, and additional support resources,” the spokesperson said.
See the release below.
Top Stories
– Trump and Kennedy Seek To Relax Safeguards for AI Healthcare Tools
– Map: The states monitoring hantavirus exposures after cruise ship outbreak
– US drug overdose deaths dropped for third straight year in 2025, CDC data shows
– Makary’s exit creates new uncertainty at FDA
– RFK Jr. Swaps Vaccine Talk for Healthy Foods and Reading to Tots in Push To Woo Voters
– RFK Jr.’s next vaccine moves could upend White House election-year messaging
Press Releases
– Eden and GenoPalate: Announce strategic partnership to redefine the future of GLP-1 care
